Peptides for Gut Health
& Leaky Gut
70% of your immune cells live in and around your gut lining. When that lining breaks down, the consequences don't stay in your digestive system — they reach into your brain, your immunity, your skin, your joints, and your mood. BPC-157 was literally discovered in the stomach. Here's what the research says about using it to repair the damage.
Gut Health — How Central It Really Is
Most people think of gut health as a digestive issue. The biology says otherwise.
Why the Gut Is Your Largest Immune Organ — Not Just a Digestive One
Most people think of the gut as a tube that processes food. That's a fraction of what it actually is. The gastrointestinal tract is the body's largest immune organ — home to approximately 70% of the body's total immune cells, housed in a specialized tissue called the gut-associated lymphoid tissue (GALT). It's also the primary site of serotonin production, a critical regulator of the autonomic nervous system, and the home of trillions of microbes that collectively outnumber your body's cells.
Running through the center of all of this is a single layer of epithelial cells, connected by proteins called tight junctions, that separates the inside of your gut from everything else. This barrier is only one cell thick. When those tight junctions are intact, they let nutrients through while keeping pathogens, undigested food particles, and bacterial fragments out. When they break down — a condition known as intestinal hyperpermeability, or "leaky gut" — those unwanted substances enter the bloodstream directly.
The immune system sees these foreign particles and responds. Inflammation signals fire. The immune response that was meant to be localized becomes systemic. And because 70% of your immune cells live right there at the barrier, the consequences of that breakdown are immediate, broad, and far-reaching — well beyond the gut itself.
The gut communicates bidirectionally with both the brain (via the vagus nerve) and the immune system (via GALT). When the gut barrier fails, it doesn't just cause digestive symptoms — it dysregulates all three systems at once.
Conditions Downstream of Leaky Gut
One root cause — broken tight junctions — can drive a cascade of seemingly unrelated conditions throughout the body. This is why leaky gut is so often missed: the symptoms appear elsewhere.
"BPC-157 wasn't designed for the gut — it was isolated from the gut. The body had already solved this problem. We just learned how to use what it made."
Gut Symptoms — And What They're Telling You
- Bloating, Gas & Abdominal DistensionThe most universal gut complaint. Driven by dysbiosis (imbalanced gut microbiome), SIBO (small intestinal bacterial overgrowth), impaired gut motility, or inflammatory disruption of the intestinal environment. BPC-157 addresses the inflammatory component while supporting the motility and repair processes that normalize gut function.
- IBS — Alternating Diarrhea & ConstipationIrritable bowel syndrome is defined by functional gut dysregulation without identifiable structural disease — but the underlying biology is real. Gut lining inflammation, dysbiosis, and impaired ENS (enteric nervous system) function are well-documented drivers. BPC-157's restoration of gut motility and mucosal integrity directly addresses these mechanisms.
- Food Sensitivities That Keep ExpandingA classic leaky gut pattern — new food sensitivities developing over months or years. As the gut barrier breaks down, incompletely digested food proteins enter the bloodstream and trigger immune responses. The immune system "learns" to react to more foods over time. Healing the barrier stops new sensitivities from forming and often reduces existing ones.
- IBD — Crohn's & Ulcerative ColitisInflammatory bowel disease involves active mucosal inflammation, ulceration, and barrier breakdown. BPC-157 has the most extensive gut-specific research of any peptide — directly relevant to IBD through its mucosal healing, cytokine modulation, and restoration of gut blood flow via angiogenesis.
- GERD & Acid RefluxGastroesophageal reflux disease is driven by lower esophageal sphincter dysfunction, mucosal inflammation, and often SIBO-driven gas pressure pushing acid upward. BPC-157's origin as a gastric protein means it has direct affinity for upper GI tissues — with documented protective effects on the esophageal mucosa.
- Anxiety, Low Mood & Brain Fog Alongside Gut SymptomsThe gut-brain connection is bidirectional and immediate. Many people with chronic gut issues notice their mood and cognitive clarity track directly with their gut symptoms — better gut days produce clearer thinking and calmer mood. This isn't coincidence. It's the 90% serotonin-in-the-gut fact expressing itself directly.
How BPC-157 & the Stack Repair the Gut
-
1Tight junction restoration — BPC-157's primary gut mechanism is the upregulation of proteins that form and maintain tight junctions — the molecular "seals" between epithelial cells that constitute the gut barrier. This directly addresses intestinal hyperpermeability at the structural level, stopping the leak rather than just managing its consequences.
-
2Mucosal angiogenesis — restoring blood flow to the gut lining — Like all tissue healing, gut repair requires blood supply. BPC-157 stimulates new blood vessel formation in the intestinal mucosa — restoring the oxygen and nutrient delivery that supports active epithelial cell turnover. This is particularly relevant in IBD, where mucosal vascularity is significantly compromised.
-
3Anti-inflammatory — without suppressing repair signals — BPC-157 reduces intestinal inflammation through nitric oxide modulation and cytokine regulation without blocking the inflammatory signals that the gut uses to coordinate its own repair. This is the same mechanism that distinguishes it from NSAIDs in the joint pain context — it reduces the fire without disabling the fire brigade.
-
4Gut motility normalization — BPC-157 has demonstrated effects on gut motility in both directions — reducing hypermotility (diarrhea-dominant patterns) and stimulating sluggish motility (constipation-dominant patterns). This bidirectional normalization reflects its action through the enteric nervous system rather than simply suppressing or stimulating a single pathway.
-
5KPV — mucosal anti-inflammatory & α-MSH restoration — KPV (Lys-Pro-Val), the tripeptide fragment of α-MSH covered in the CIRS guide, has potent local anti-inflammatory effects in the gut mucosa specifically. It reduces pro-inflammatory cytokines (TNF-α, IL-6) directly in the intestinal lining and supports the mucosal immune environment. In the gut context, KPV is used for its direct mucosal effects — making it an ideal complement to BPC-157's structural repair.
-
6Vagus nerve support — the gut-brain highway — BPC-157 has documented effects on vagal tone — the signaling pathway that connects the gut and brain bidirectionally. Improved vagal tone restores the parasympathetic "rest and digest" state that healthy gut function depends on, and supports the mood-regulatory role of the gut-brain axis. This is the mechanism behind the anxiety and mood benefits frequently reported alongside gut healing.
Protocols for Gut Health & Leaky Gut
BPC-157 is genuinely bioavailable orally — which is unusual and clinically significant. It was designed by the stomach to survive digestion. This shapes how the protocol is built.
Peptide Therapy vs. Conventional Gut Treatments
| Approach | Mechanism | Barrier Repair | Long-Term Outcome |
|---|---|---|---|
| BPC-157 + Stack This Page | Tight junction restoration, mucosal angiogenesis, motility normalization, cytokine regulation | Active structural repair of the epithelial barrier | Addresses root biology — durable benefit with appropriate cycling |
| PPIs (Proton Pump Inhibitors) | Suppresses stomach acid production | No — doesn't address gut barrier integrity | Symptom management; long-term use associated with nutrient malabsorption and microbiome disruption |
| Probiotics | Restore beneficial bacterial populations | Indirect — improved microbiome supports barrier function | Useful foundational support; doesn't directly repair structural barrier damage |
| L-glutamine | Primary fuel for enterocytes (gut lining cells) | Partial — supports barrier maintenance, not active repair of damage | Good foundational supplement; less potent than BPC-157 for structural repair |
| Biologics (anti-TNF) | Suppress specific inflammatory cytokines (e.g., TNF-α) | Indirect — reduced inflammation allows some repair | Effective for moderate-severe IBD; significant side effect and immunosuppression profile |
| Elimination diets | Remove inflammatory triggers | Indirect — removes ongoing damage stimulus | Essential foundation; doesn't repair existing barrier damage alone |
What to Expect and When
- Day 3–7 Motility normalization beginsOne of the earliest and most reliably reported effects — bloating reduces, bowel movements become more regular and predictable. This reflects BPC-157's rapid action on the enteric nervous system rather than the slower structural repair that follows. Many people notice meaningful digestive comfort improvement within the first week.
- Week 1–2 Inflammation reduction & mood liftAs mucosal inflammation reduces, the gut-brain axis communication improves. Many people notice reduced anxiety, clearer thinking, and improved mood alongside the digestive changes — this is the serotonin and vagal tone dimension expressing itself as the gut environment normalizes.
- Week 2–4 Barrier repair consolidatingTight junction restoration is a structural process that takes weeks. By week 3–4, food sensitivities often begin to reduce as fewer undigested particles are entering the bloodstream. Systemic symptoms — joint inflammation, skin reactivity, brain fog — may start to improve as the upstream driver is addressed.
- Week 4–8 Mucosal healing (IBD presentations)For active mucosal inflammation in IBD or severe leaky gut, the deeper healing — mucosal tissue repair and vascular restoration — consolidates in this window. The KPV anti-inflammatory action and BPC-157 angiogenic repair work together over this timeframe. Labs (CRP, fecal calprotectin) should show improvement at the 6–8 week mark.
- Month 2–4 Downstream condition improvementAs the gut heals and systemic inflammation reduces, the conditions downstream of leaky gut — skin issues, joint inflammation, anxiety, chronic fatigue — typically improve meaningfully in this window. This is when the full systemic benefit of healing the root becomes apparent.
What Has to Come Before & Alongside Peptides
Frequently Asked Questions
Intestinal hyperpermeability — the scientific term for what's colloquially called leaky gut — is a well-documented and measurable physiological state. It has been studied extensively in the context of IBD, celiac disease, IBS, and more recently in its role as a systemic driver of inflammation. The term "leaky gut" is not an official diagnostic category in conventional medicine, which is partly why it's controversial — but the underlying biology of tight junction dysfunction and its downstream consequences are genuinely well-established in peer-reviewed literature. It's a real phenomenon; the controversy is mostly about nomenclature and diagnostic criteria.
BPC-157 has extensive preclinical research specifically in IBD models — including Crohn's-like and ulcerative colitis models — consistently showing mucosal healing, cytokine reduction, and restoration of gut architecture. Human clinical data is still emerging, but the mechanistic overlap with IBD pathology is direct and compelling. Many functional medicine practitioners incorporate BPC-157 into IBD protocols as a complement to — not a replacement for — conventional IBD management. Always involve your gastroenterologist before modifying any IBD treatment regimen. Active severe flares may require conservative dosing and close monitoring.
For gut-targeted use, taking BPC-157 orally on an empty stomach maximizes its mucosal contact time — the peptide reaches the gut lining before food arrives and dilutes or moves it along. This increases local concentration at the site of intended action. For systemic effects (not gut-specific), the timing matters less — but the empty stomach approach is the standard recommendation for gut health protocols because it optimizes the local delivery that is BPC-157's primary advantage over injections in this application.
The gut-brain axis is a bidirectional communication system connecting the enteric nervous system (the gut's own neural network) to the central nervous system via the vagus nerve, hormonal signals, and immune messengers. The gut produces approximately 90% of the body's serotonin — not the blood-brain barrier-crossing kind, but the kind that regulates gut motility and feeds back to the brain via the vagus nerve. When the gut is inflamed and the barrier is compromised, this signaling is disrupted, and systemic inflammatory cytokines crossing into the brain directly impair mood and cognitive function. Many people notice that gut healing produces mood improvements before the gut symptoms are fully resolved — the brain-gut connection is that immediate.
The answer depends significantly on the severity and chronicity of the condition. For mild-to-moderate leaky gut symptoms, a 4–8 week course under physician guidance often produces meaningful improvement. For active IBD, post-antibiotic gut dysbiosis, or long-standing barrier dysfunction, longer courses of 8–12 weeks or more may be needed — always with appropriate cycling and physician oversight. The foundational interventions (diet, probiotics, glutamine) should continue throughout and after the peptide course, as they maintain the gut environment that BPC-157 has helped restore.
Leaky Gut Protocol Guide
Full dosing protocols by condition, the BPC-157 + KPV stack breakdown, how to test gut permeability, a step-by-step reintroduction guide, and a provider conversation script.
Peptides for Hair Loss & Skin Aging
Hair thinning and skin aging aren't cosmetic problems — they're biological ones. The same peptide that drives tissue repair and gene regulation throughout your body also governs the health of your skin and follicles. When it declines, the signs are visible. When it's restored, so are the results.
The Scale of the Problem
Hair and skin concerns are near-universal with age — and they're driven by measurable biology, not just genetics.
What's Actually Driving Hair Loss & Skin Aging
Hair loss and skin aging are often treated as separate problems — one managed with minoxidil or finasteride, the other with retinol and moisturizers. But they share a common biological root: the age-related decline of the repair, regeneration, and gene-regulation systems that once kept both in healthy working order.
At the center of that decline is GHK-Cu — a copper-binding tripeptide your body produces naturally that falls from approximately 200 ng/mL at age 20 to below 80 ng/mL by age 60. As GHK-Cu drops, three critical processes slow simultaneously: collagen and elastin synthesis in the dermis, hair follicle activation and growth factor signaling in the scalp, and the broad gene regulatory activity that keeps inflammation and oxidative stress in check at the cellular level.
Alongside GHK-Cu decline, the broader hormonal environment shifts. Growth hormone output falls, reducing the systemic anabolic signaling that supports both skin thickness and hair cycle regulation. Estrogen drops in women, removing its protective effect on collagen production and hair follicle longevity. The result is a compounding biological process — not just cosmetic wear and tear.
The Collagen & GHK-Cu Decline — Side by Side
Both GHK-Cu plasma levels and skin collagen density decline in parallel — each falling approximately 60% between ages 20 and 60. The close correlation is why GHK-Cu levels have been proposed as a direct biomarker of biological skin age.
Signs of Declining Skin & Hair Biology
These aren't just cosmetic changes — each one reflects a specific biological shift that peptide therapy can address at the source.
- Hair Thinning & Increased SheddingAs GHK-Cu falls, the VEGF and FGF growth factor signaling that keeps hair follicles in the active (anagen) growth phase weakens. Follicles spend more time in the resting and shedding phases. The result is visible thinning, reduced hair diameter, and increased daily shedding — often starting subtly in the 30s and accelerating through the 40s and 50s.
- Skin Thinning & Loss of FirmnessThe dermis loses thickness as collagen density falls ~1% per year after age 25. Skin becomes less resilient, more prone to fine lines, and loses the plump firmness of younger tissue. This is a structural change driven by reduced fibroblast activity — not simply surface dryness.
- Fine Lines, Wrinkles & SaggingCollagen provides structure; elastin provides recoil. As both decline, skin loses its ability to snap back after movement. Fine lines deepen into wrinkles. The jawline and under-eye areas — where the dermis is thinnest — show changes earliest.
- Slower Wound Healing & BruisingGHK-Cu's original identification was through wound healing research. As levels fall, the coordination of tissue repair slows. Cuts take longer to close, bruises linger, and the quality of scar tissue worsens. Many people in their 40s and 50s first notice this as a change from how quickly they healed in their 20s.
- Dull Skin & Uneven ToneSkin cell turnover slows with age as the signaling that drives epidermal renewal weakens. Dead cells accumulate on the surface longer before being shed. The result is dullness, uneven pigmentation, and a loss of the translucency associated with younger skin.
- Increased Skin Sensitivity & InflammationAs GHK-Cu's gene-regulatory activity declines, the skin's anti-inflammatory defense weakens. Reactive oxygen species accumulate. Low-level inflammation increases. The skin becomes more reactive to environmental triggers, sun exposure, and products that were previously well-tolerated.
"GHK-Cu modulates the expression of approximately 31% of human genes tracked in aging studies. No other peptide in clinical use has demonstrated this breadth of gene influence."
Research by Loren Pickart & Anna Margolina
How GHK-Cu Addresses Hair & Skin Aging
-
1Fibroblast activation & collagen synthesis — GHK-Cu directly activates fibroblast cells in the dermis, upregulating the genes responsible for collagen I, collagen III, and elastin synthesis. This restores the structural protein production that young skin performs naturally but aging skin progressively loses. The result is measurably increased dermis thickness and improved skin elasticity with consistent use.
-
2Hair follicle activation & growth factor upregulation — GHK-Cu stimulates VEGF (vascular endothelial growth factor) and FGF (fibroblast growth factor) in scalp tissue, improving blood flow to follicles and upregulating the growth signals that maintain the hair growth cycle. It also activates the Wnt/β-catenin pathway — a key regulator of follicle cycling that declines with age. Hair shaft diameter improvements and reduced shedding typically require 8–12 weeks of consistent scalp application.
-
3Broad gene regulation — 31% of aging-tracked genes — Beyond collagen and hair, GHK-Cu modulates approximately 31% of the human genes tracked in aging studies, including genes governing inflammation response, oxidative stress defense, DNA repair, and immune modulation. This systemic anti-aging gene activity is why GHK-Cu produces results that go well beyond what any topical skincare product can achieve.
-
4Wound healing & tissue remodeling — GHK-Cu coordinates the tissue remodeling phase of wound repair — promoting orderly collagen deposition, reducing scar formation, and stimulating the migration of repair cells. It also reduces the reactive oxygen species that accumulate at injury sites. This is why GHK-Cu stacks synergistically with BPC-157 in comprehensive repair protocols.
-
5Copper delivery to enzymatic processes — GHK-Cu carries copper ions into tissue where copper-dependent enzymes — particularly lysyl oxidase (essential for collagen crosslinking and tensile strength) and superoxide dismutase (key antioxidant) — require it to function. Low-level copper delivery through GHK-Cu is more bioavailable and tissue-targeted than systemic copper supplementation.
Topical, Oral Liposomal, or Injectable — Which Is Right for You?
GHK-Cu is unique among peptides in that it's genuinely effective through multiple delivery routes — each with a different mechanism and best-use case. Understanding the difference is essential for getting results.
Most peptides are limited to one effective delivery route. GHK-Cu is a rare exception — it works topically for local skin and scalp benefit, orally in liposomal form for systemic gene regulation, and subcutaneously for the strongest systemic effect. The right route depends entirely on your primary goal.
Local / targeted
Systemic
Max systemic
Which Peptides Are Used for Hair Loss & Skin Aging?
GHK-Cu is the anchor — but the full protocol includes supporting peptides that address the hormonal and systemic factors driving the decline.
Copper Monitoring & Cycling — Why It Matters
GHK-Cu's copper-carrying function is central to its mechanism — but it also means copper accumulation is a genuine consideration with extended use, particularly at systemic doses. This is one of the most important clinical nuances of GHK-Cu protocols and one that's frequently glossed over in consumer content.
Monitor serum copper and ceruloplasmin levels with extended systemic use. For topical-only use at standard concentrations, copper accumulation is not a meaningful concern. For oral liposomal or injectable protocols, serum copper should be checked at baseline and again at 3 months. Cycle off systemically every 8–12 weeks or as directed by your provider. Signs of excess copper include nausea, headache, and gastrointestinal upset — stop use and consult your provider if these occur.
A Realistic Timeline — What to Expect and When
GHK-Cu results build gradually. Understanding the timeline prevents premature discontinuation — the most common reason people don't see results.
- Week 1–3 Skin surface changesImproved skin hydration and surface texture are often the first changes noticed — smoother feel, slightly more luminous appearance. These early effects reflect GHK-Cu's influence on the epidermal surface rather than the deeper structural changes that take longer.
- Week 4–8 Reduced shedding & early firmnessHair shedding typically begins to reduce as VEGF and follicle growth factor signaling restores. Early improvements in skin firmness and fine line depth may be visible. This is the point where many people first question whether it's working — consistency matters here.
- Week 8–12 Measurable hair and skin changesThe 8–12 week window is where most clinical studies show measurable results: improved hair shaft diameter, increased dermis thickness on ultrasound, visible reduction in fine lines, improved skin tone evenness. This is the minimum timeframe for meaningful assessment.
- Month 3–6 Collagen density & hair volumeDeeper structural changes — actual dermis thickening and collagen density restoration — build over months, not weeks. Hair volume improvement (new follicle activation, increased diameter, more hairs in growth phase) typically reaches its plateau in this window.
- Ongoing (cycling) Maintenance with cyclingResults are maintained with continued cycling protocols. Discontinuation typically leads to gradual return toward baseline over 3–6 months — GHK-Cu is restoring biology, not permanently altering it. Many people incorporate it as a long-term foundation of their skin and hair maintenance protocol.
GHK-Cu vs. Conventional Approaches
| Approach | Mechanism | Hair | Skin | Gene Regulation |
|---|---|---|---|---|
| GHK-Cu | Activates fibroblasts, follicle growth factors, 31% of aging-tracked genes | ✓ Follicle activation, VEGF upregulation | ✓ Collagen synthesis, dermis thickening | ✓ Broad anti-aging gene modulation |
| Minoxidil | Vasodilation — increases blood flow to follicles | ✓ Hair growth (requires continuous use) | — | — |
| Finasteride | DHT reduction — slows androgen-driven hair loss | ✓ Male pattern hair loss only | — | — |
| Retinol / Retinoids | Increases cell turnover, mild collagen stimulation | — | ✓ Surface improvement; less dermis impact | Limited |
| Topical collagen creams | Surface moisturization only — cannot penetrate dermis | — | Surface only — no collagen synthesis effect | — |
| Platelet-Rich Plasma (PRP) | Growth factor delivery from patient's own blood | ✓ Effective but expensive, clinical setting required | ✓ Skin rejuvenation | Limited |
What Supports GHK-Cu's Effectiveness
Frequently Asked Questions
Most consumer copper peptide skincare contains very low concentrations of GHK-Cu (often below 0.1%) that are sufficient for surface-level benefits but insufficient for meaningful fibroblast activation. Clinical protocols typically use 1–2% topical concentrations for measurable dermis-level effects. For systemic gene regulation, oral liposomal or injectable forms are required — these are fundamentally different from any over-the-counter skincare product. The ingredient is the same; the concentration, formulation, and delivery route determine whether you're getting cosmetic or therapeutic effects.
Yes — and the combination is frequently used in clinical practice. Minoxidil works through vasodilation (blood flow), finasteride through DHT reduction, and GHK-Cu through follicle growth factor activation and gene regulation. They address different aspects of hair loss through different mechanisms, making them complementary rather than redundant. Many practitioners treat minoxidil or finasteride as the "holding" therapy and GHK-Cu as the regenerative component.
For topical-only use, the systemic copper absorption is minimal and copper accumulation is not a meaningful concern. For systemic use (oral liposomal or injectable), copper monitoring is recommended as described in the cycling section above. The key protective measure is ensuring adequate zinc intake — copper and zinc compete for absorption, and maintaining a healthy copper-zinc ratio is the primary safeguard against copper excess. Most people who monitor appropriately and cycle as recommended do not develop copper accumulation issues.
GHK-Cu addresses the growth factor and gene regulation dimensions of hair loss, which contribute to androgenetic alopecia alongside the DHT-driven follicle miniaturization that finasteride targets. GHK-Cu alone is not sufficient to halt advanced androgenetic alopecia, but it is an effective addition to a DHT-blocking protocol — supporting follicle health, improving the micro-environment for remaining follicles, and potentially recovering some thinning follicles that haven't yet fully miniaturized. It also addresses the diffuse hair thinning that affects women, where DHT is a less dominant driver.
GHK-Cu restores the biological signaling that supports collagen production and follicle activity — it doesn't create permanent structural changes. When discontinued, the body gradually returns toward its baseline over 3–6 months as the signaling benefit fades. This is why most practitioners recommend it as a long-term maintenance protocol with appropriate cycling, rather than a short-course treatment. The goal is sustained restoration of biological function, not a one-time fix.
Peptide Protocol Guide
Full protocol breakdowns for topical, oral, and injectable GHK-Cu, copper monitoring guidance, stacking options with Epithalon and BPC-157, and a provider conversation script.
Chronic Inflammation & CIRS — When the Immune System Won't Stand Down
CIRS affects an estimated 8 in 10 patients with chronic unexplained health complaints — yet most are never diagnosed.
Chronic Inflammatory Response Syndrome (CIRS) is a multi-system illness triggered by exposure to biotoxins — primarily mold (water-damaged buildings), Lyme disease, post-viral illness, and ciguatera. In genetically susceptible individuals (approximately 25% of the population carry the HLA-DR variants that prevent normal biotoxin clearance), a single significant exposure can trigger a self-perpetuating inflammatory cascade that doesn't resolve when the exposure ends.
The result is a condition that standard medicine consistently fails to diagnose — because standard blood panels almost always come back normal. Meanwhile the patient experiences a constellation of symptoms that looks like chronic fatigue, fibromyalgia, depression, cognitive decline, and autoimmune disease simultaneously.
The MARCONS connection is one of the most important and underrepresented aspects of CIRS. MARCONS (Multiple Antibiotic Resistant Coagulase Negative Staph) colonizes the nasal passages in many CIRS patients — and actively destroys α-MSH, the body's primary anti-inflammatory hormone. This creates a vicious cycle: CIRS depletes α-MSH, which allows MARCONS to thrive, which further destroys α-MSH, which deepens the inflammatory cascade.
CIRS is not a diagnosis of exclusion or a psychological condition. It is a specific, measurable immune dysregulation with identifiable biomarkers, a known genetic susceptibility mechanism, and a growing body of evidence-based treatment protocols. The Shoemaker Protocol — developed by Dr. Ritchie Shoemaker — remains the most validated framework for CIRS diagnosis and treatment.
What Drives CIRS?
Four primary triggers — one common downstream mechanism.
The most common CIRS trigger. Mycotoxins from water-damaged buildings are lipid-soluble and cannot be cleared by the liver in HLA-DR susceptible individuals. They recirculate continuously, maintaining the inflammatory trigger indefinitely.
Borrelia and associated co-infections trigger the same HLA-DR-mediated biotoxin retention pathway. Many "chronic Lyme" cases are more accurately understood as CIRS driven by Lyme biotoxins rather than active ongoing infection.
Post-viral syndromes — including Long COVID — increasingly fit the CIRS framework. Many Long COVID patients carry the same HLA-DR susceptibility variants. CIRS-trained practitioners are applying Thymosin Alpha-1 and KPV to Long COVID with meaningful clinical results.
CIRS depletes α-MSH — the body's primary anti-inflammatory hormone. Low α-MSH allows MARCONS bacteria to colonize the nasal passages. MARCONS actively destroys more α-MSH. This self-perpetuating cycle is why CIRS doesn't resolve without targeted intervention.
Peptides for CIRS & Chronic Inflammation
Five peptides addressing different layers of the CIRS cascade — with Thymosin Alpha-1 and KPV as the anchors.
-
★ Anchor — Immune Modulation Thymosin Alpha-1 (Tα1) Thymosin Alpha-1 is the primary immune modulator in the CIRS protocol. It restores appropriate immune regulation — neither suppressing nor over-activating the immune response, but normalizing the dysregulated TGF-β1 driven inflammatory cascade that defines CIRS. It also directly addresses the elevated TGF-β1 that is one of CIRS's most consistent biomarkers. Used in courses alongside KPV for the full immune restoration effect.
-
★ Anchor — α-MSH Restoration KPV (Lys-Pro-Val) KPV is a tripeptide fragment of α-MSH — the anti-inflammatory hormone destroyed by MARCONS in CIRS patients. KPV directly restores the α-MSH signaling pathway, breaking the MARCONS-α-MSH destruction cycle. Critical protocol note: KPV must be run for a minimum of 4 months without cycling off early. The most common practitioner error in CIRS treatment is discontinuing KPV before the α-MSH pathway is fully restored — which allows the cycle to re-establish.
-
Gut & systemic repair BPC-157 CIRS reliably damages gut integrity — and gut permeability is both a consequence and a driver of ongoing systemic inflammation. BPC-157 repairs the gut lining, reduces intestinal inflammation, and addresses the leaky gut component of CIRS that keeps the inflammatory cycle running. Also relevant for the musculoskeletal pain that commonly accompanies CIRS.
-
Systemic tissue repair TB-4 Fragment (Thymosin Beta-4 Fragment) Supports systemic tissue repair and immune modulation. Works synergistically with BPC-157 for comprehensive healing. Raises underactive immune response — relevant to the immune imbalance driving CIRS.
-
Sleep foundation — nearly always indicated Epithalon CIRS patients almost universally experience disrupted restorative sleep. Epithalon restores deep sleep and REM through pineal gland support — which also supports the same α-MSH-related pathway disrupted by CIRS. Additionally addresses the accelerated telomere shortening driven by chronic systemic inflammation.
KPV Minimum Duration: KPV must be run for a minimum of 4 months continuously. Cycling off early — before the α-MSH pathway is restored — allows MARCONS to re-establish and the destruction cycle to resume. This is the single most common protocol error in CIRS treatment. Work with a CIRS-trained practitioner to determine your specific duration based on α-MSH lab restoration.
The Labs That Reveal What Standard Panels Miss
Standard blood work almost always comes back normal in CIRS. These specific markers reveal the condition.
| Biomarker | What It Measures | In CIRS | Why It Matters |
|---|---|---|---|
| TGF-β1 | Master immune regulator | ↑ Elevated | Primary driver of CIRS immune dysregulation. Target for Thymosin Alpha-1. |
| α-MSH | Anti-inflammatory hormone | ↓ Low | Depleted by MARCONS. Restoration via KPV is central to recovery. |
| MMP-9 | Inflammatory tissue enzyme | ↑ Elevated | Breaks down blood-brain barrier. Drives brain fog and physical symptoms. |
| C4a | Complement inflammation marker | ↑ Elevated | Highly elevated in active CIRS. Useful for tracking treatment response. |
| IGF-1 | Growth hormone status | ↓ Low | Commonly suppressed in CIRS. Relevant to fatigue and recovery capacity. |
| VCS Test | Visual Contrast Sensitivity | ↓ Impaired | Free screening tool (survivingmold.com). Abnormal in ~92% of CIRS cases. |
Source removal first. No peptide protocol will produce lasting results while ongoing biotoxin exposure continues. Mold remediation, binder therapy (cholestyramine, activated charcoal), MARCONS clearance, and anti-inflammatory diet are the non-negotiable foundation. Peptide therapy amplifies a good foundation — it doesn't replace it.
This guide is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. CIRS requires diagnosis and management by a qualified, trained physician. Peptide therapy for CIRS is used off-label and should only be undertaken under physician supervision with appropriate lab monitoring. InformedPeptides.com and its authors are not liable for actions taken based on the content of this page.